Phase II evaluation of bryostatin-1 in metastatic melanoma

Melanoma Research

Volumn 11, Issue 2, 2001, Pages 183-188

  Bedikian, A Y ^a   Plager, C ^a   Stewart, J R ^a   O'Brian, C A ^a   Herdman, S K ^a   Ross, M ^a   Papadopoulos, N ^a   Eton, O ^a   Ellerhorst, J ^a   Smith, T ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bryostatin 1; Chemotherapy; Melanoma

Indexed keywords

BRYOSTATIN 1; NSC 339555; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; METASTASIS; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HUMANS; LACTONES; MACROLIDES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN ISOFORMS; PROTEIN KINASE C; TIME FACTORS;

EID: 0035035103     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200104000-00014     Document Type: Article

References (23)

1. Systemic therapy for advanced cutaneous melanoma
2. Isolation and structure of bryostatin-1
3. Bryostatin-1 induces apoptosis in LNCaP human cancer cells overexpressing protein kinase C (PKC) α or PKCε
4. Bryostatin-1 induces growth arrest and apoptosis in a highly metastatic mammary epithelial cell line
5. Successful treatment of murine melanoma with bryostatin-1
6. The bryostatin-1 inhibits growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 26-epi-bryostatin-1
7. The antineoplastic agent bryostatin-1 (Bryo-1) potentially activates monocytes to produce cytokines. Synergy with interleukin-2 (IL-2)
8. Phase I study of bryostatin-1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo
9. A phase I and immunologic study of bryostatin-1 in patients with solid tumors
10. Bryostatin-1 and IFN-γ synergize for the expression of the inducible nitric oxide synthase gene and for nitric oxide production in murine macrophages
11. A phase I study of intravenous bryostatin-1 in patients with advanced cancer
12. Phase I study of bryostatin-1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
13. Optimal two-stage designs for phase II clinical trials
14. Covalent modification of protein kinase C isozymes by the inactivating peptide substrate analog N-biotinyl-Arg-Arg-Arg-Cys-Leu-Arg-Arg-Leu: Evidence that the biotinylated peptide is an active-site affinity label
15. A phase II study of bryostatin-1 in metastatic melanoma
16. A phase I trial of bryostatin-1 in patients with advanced malignancy using a 24 hour intravenous infusion
17. Phase Ib trial of bryostatin-1 in patients with refractory malignancies
18. NCIC CTG randomized phase II study of two schedules of bryostatin 1 (NSC339555) in patients with advanced malignant melanoma
19. Treatment of patients with metastatic melanoma with bryostatin-1 - A phase II study
20. Deletion of specific protein kinase C subspecies in human melanoma cells
21. Translocation and downregulation of protein kinase C isoenzymes -alpha and -epsilon by phorbol ester and bryostatin-1 in human keratinocytes and fibroblasts
22. Sequential treatment of chronic lymphocytic leukemia with bryostatin 1 and α-interferon
23. Sensitization of human cervical carcinoma cells to cis-diammminedichloroplatinum(II) by bryostatin-1